Centchroman (CC), a triphenylethylene Selective Estrogen Receptor Modulator (SERM) has been considered a potential anti-breast cancer drug in ER-positive (MCF-7)/−negative (MDA MB-231) Human Breast Cancer Cells (HBCCs) as well as with all stages of hormone-responsive breast cancer [2]–[4]. Here, ESR1 is linked to breast carcinoma.